| Project/Area Number |
21249047
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General internal medicine (including Psychosomatic medicine)
|
|---|
| Research Institution | University of Toyama |
|---|
Principal Investigator |
TOHDA Michihisa 富山大学, 和漢医薬学総合研究所, 准教授 (20207525)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOMATSU Katsuko 富山大学, 和漢医薬学総合研究所, 教授 (50225570)
NAMIKI Takao 千葉大学, 医学(系)研究科(研究院), 准教授 (20312001)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
GOTO Hirozou 北聖病院(富山市), 医師 (40313598)
TOHDA Chihiro 富山大学, 和漢医薬学総合研究所, 准教授 (10272931)
TEI Miwa 北里大学, 北里生命科学研究所, 特任助教 (50464029)
|
|---|
| Research Collaborator |
YOKAWA Takashi BioView 社, 代表取締役
MONRUDEE Sukma シラパコーン大学 (タイ国), 薬学部, 助教
|
|---|
| Project Period (FY) |
2009-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥41,340,000 (Direct Cost: ¥31,800,000、Indirect Cost: ¥9,540,000)
Fiscal Year 2013: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2012: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2011: ¥7,280,000 (Direct Cost: ¥5,600,000、Indirect Cost: ¥1,680,000)
Fiscal Year 2010: ¥8,450,000 (Direct Cost: ¥6,500,000、Indirect Cost: ¥1,950,000)
Fiscal Year 2009: ¥18,070,000 (Direct Cost: ¥13,900,000、Indirect Cost: ¥4,170,000)
|
|---|
| Keywords | 和漢薬 / 統合薬理学 / MRI / 病態モデル / 遺伝子発現 / 機能性精神疾患 / 3D-HPLC / テーラーメード医療 / 薬物感受性 / 病態モデル動物 / ヒトによる実験 / 中枢神経 / 消化器系 / 上行性神経 / 補中益気湯 / 脳基底部 / 初代培養細胞 / うつ病 / セロトニン2C受容体 / 学習性無気力動物 / ツメガエル卵母細胞 / BNIP-3 / 十全大補湯 / STAT3 |
|---|
| Research Abstract |
The Wakan-yaku is systematized medical care that has been practiced for several hundred years in Japan. Based on the theories of Wakan-yaku and using various Wakan-yaku prescriptions for depression treatment, the experimental studies for 1) novel-classification of depressive disorders, 2) establishment of highly effective drug treatment including the Wakan-yaku prescriptions, and 3) to supply of novel basic knowledge for development of new antidepressants were carried out. The following results were obtained; Wakan-yaku effects in the brain of drug-sensitive/-insensitive human and depression-model mice by image analytical method (MRI), the integrated viewpoint of the action mechanism using the model animal, identification and the significance of genes which changes the expression by Wakan-yaku or the constitutions in cultured cells, and the bioassay of active compounds by using the combined methods of electrophysiological technique with 3D-HPLC analysis/purification.
|
